Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 14/20 | 0.60 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.56 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 0.56 |
| ▸ | REN | P00797 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17226103 | 0.95 | PLK1 (0.55) | PLK1PLK3PLK2REN | |
| SCHEMBL464367 | 0.92 | PLK1 (0.61) | PLK1PLK3PLK2REN | |
| SCHEMBL7835049 | 0.92 | PLK1 (0.61) | PLK1PLK3PLK2REN | |
| SCHEMBL464336 | 0.92 | PLK1 (0.61) | PLK1PLK3PLK2REN | |
| SCHEMBL464067 | 0.91 | PLK1 (0.63) | PLK1PLK3PLK2REN | |
| SCHEMBL22930126 | 0.90 | PLK1 (0.70) | PLK1PLK3PLK2REN | |
| SCHEMBL22930127 | 0.90 | PLK1 (0.70) | PLK1PLK3PLK2REN | |
| SCHEMBL22930164 | 0.90 | PLK1 (0.70) | PLK1PLK3PLK2REN | |
| SCHEMBL464377 | 0.90 | PLK1 (0.70) | PLK1PLK3PLK2REN | |
| SCHEMBL464186 | 0.90 | PLK1 (0.58) | PLK1PLK3PLK2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175038-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2010132869-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK2, PLK4 | PLK1 1/4885PLK3 4/4885PLK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.